<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Second Sight Medical Products, Inc.

    Second Sight Medical Products, Inc.

    The recognized global leader in neuromodulation devices to treat blindness, the co...

    The recognized global leader in neuromodulation...

    Filing Type:    PU
    MediciNova, Inc.

    MediciNova, Inc.

    MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...

    MediciNova, Inc. is a publicly-traded biopharma...

    Filing Type:    PU
    SI-BONE, Inc.

    SI-BONE, Inc.

    SI-BONE is a medical device company that has pioneered a proprietary minimally inv...

    SI-BONE is a medical device company that has pi...

    Filing Type:    PU
    Merit Medical Systems, Inc.

    Merit Medical Systems, Inc.

    Founded in 1987, Merit Medical set out to build the world’s most customer-focuse...

    Founded in 1987, Merit Medical set out to build...

    Filing Type:    PU
    Delee Corp

    Delee Corp

    At Delee we’re fundamentally changing not only the way cancer is detected but also...

    At Delee we’re fundamentally changing not only ...

    Amount Raised:    $492,503.00
    Fundraising Status:    EC
    Filing Type:    CF
    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    ProLung, Inc.

    ProLung, Inc.

    ProLung is a medical technology company specializing in innovative predictive anal...

    ProLung is a medical technology company special...

    Filing Type:    PU
    Principia Biopharma Inc.

    Principia Biopharma Inc.

    We are a late-stage biopharmaceutical company dedicated to bringing transformative...

    We are a late-stage biopharmaceutical company d...

    Filing Type:    PU
    Aravive, Inc.

    Aravive, Inc.

    Aravive is developing treatments designed to halt progression of life-threatening ...

    Aravive is developing treatments designed to ha...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.